These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

228 related items for PubMed ID: 1612505

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
    Hainsworth JD, Grosh WW, Burnett LS, Jones HW, Wolff SN, Greco FA.
    Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
    [Abstract] [Full Text] [Related]

  • 3. A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA).
    Bertelsen K, Jakobsen A, Strøyer J, Nielsen K, Sandberg E, Andersen JE, Ahrons S, Nyland M, Hjortkjaer Pedersen P, Larsen G.
    Gynecol Oncol; 1993 Apr; 49(1):30-6. PubMed ID: 8482557
    [Abstract] [Full Text] [Related]

  • 4. Long-term results in patients with advanced epithelial ovarian carcinoma treated with a combination of cisplatin, doxorubicin, and cyclophosphamide.
    Colozza M, Mosconi AM, Gori S, Belsanti V, Basurto C, De Angelis V, Giansanti M, Tonato M.
    Am J Clin Oncol; 1997 Oct; 20(5):522-6. PubMed ID: 9345342
    [Abstract] [Full Text] [Related]

  • 5. Prospective sequential trials of induction weekly cisplatin followed by monthly cisplatin, doxorubicin, cyclophosphamide and paclitaxel and cisplatin in optimal (< or = 1 cm) stage III and IV ovarian cancer.
    Piver MS, Eltabbakh GH, Hempling RE, Recio FO, Blumenson LE.
    Eur J Gynaecol Oncol; 1998 Oct; 19(1):5-10. PubMed ID: 9476049
    [Abstract] [Full Text] [Related]

  • 6. The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP).
    Hainsworth JD, Jones HW, Burnett LS, Johnson DH, Greco FA.
    Am J Clin Oncol; 1990 Oct; 13(5):410-5. PubMed ID: 2121019
    [Abstract] [Full Text] [Related]

  • 7. High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma.
    Hainsworth JD, Burnett LS, Jones HW, Grosh WW, Johnson DH, Greco FA.
    J Clin Oncol; 1990 Mar; 8(3):502-8. PubMed ID: 2407811
    [Abstract] [Full Text] [Related]

  • 8. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S, Yeap B, Vogl S, Carbone P.
    Cancer; 1996 Feb 15; 77(4):733-42. PubMed ID: 8616766
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study.
    Omura G, Blessing JA, Ehrlich CE, Miller A, Yordan E, Creasman WT, Homesley HD.
    Cancer; 1986 May 01; 57(9):1725-30. PubMed ID: 3513943
    [Abstract] [Full Text] [Related]

  • 11. A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma.
    Bertelsen K, Jakobsen A, Andersen JE, Ahrons S, Pedersen PH, Kiaer H, Arffmann E, Bichel P, Boestofte E, Strøyer I.
    Gynecol Oncol; 1987 Oct 01; 28(2):161-9. PubMed ID: 3311924
    [Abstract] [Full Text] [Related]

  • 12. High-dose, short-duration cisplatin/doxorubicin combination chemotherapy for advanced ovarian epithelial cancer.
    Hunter RE, Griffin TW, Stevens S, Roman LD, Bokhari F, Reale FR, Tak WK, Fitzgerald TJ, Dillon MB, Rose PG.
    Cancer; 1991 Nov 01; 68(9):1890-4. PubMed ID: 1655227
    [Abstract] [Full Text] [Related]

  • 13. Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer.
    Rothenberg ML, Ozols RF, Glatstein E, Steinberg SM, Reed E, Young RC.
    J Clin Oncol; 1992 May 01; 10(5):727-34. PubMed ID: 1569445
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project.
    J Clin Oncol; 1991 Sep 01; 9(9):1668-74. PubMed ID: 1831495
    [Abstract] [Full Text] [Related]

  • 16. Accurate laboratory predictions of the clinical response of patients with advanced ovarian cancer to treatment with cyclophosphamide, doxorubicin, and cisplatin.
    Stratton JA, Kucera PR, Rettenmaier MA, Dobashi K, Micha JP, Braly PS, Berman ML, DiSaia PJ.
    Gynecol Oncol; 1986 Nov 01; 25(3):302-10. PubMed ID: 3781341
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide as an adjunct to surgery in stage Ic-II epithelial ovarian carcinoma. Gynecologic Oncology Group of the Comprehensive Cancer Center.
    Wils J, van Geuns H.
    Am J Clin Oncol; 1989 Jun 01; 12(3):251-4. PubMed ID: 2658540
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.